Clinical Trial Update: First-in-human Study of UX016 in GNEM [Phase 1, Phase 2]

View source ↗

Summary

Update on a first-in-human study of UX016 for GNE myopathy (GNEM) in Phase 1/2, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gne Myopathy

Drugs mentioned

• UX016

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: GNE Myopathy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING